← Back to News · 1 outlet · Story cluster #55789

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

How different outlets framed the same story — bias, verdict, and framing side by side.

🤖 D.R.A.F.T. Summary

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcol

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S.

Outlets covering this story

Financial Post CENTER

Only one perspective covered this story — no diversity detected

📰

Side-by-Side Outlet Comparison — Starter+

See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.

Unlock with Starter →

See plans